Skip to main content
. 2022 Nov 4;65(22):15443–15456. doi: 10.1021/acs.jmedchem.2c01391

Figure 8.

Figure 8

. Targefrin-dimer-PTX retain its ability to cause EphA2 degradation in pancreatic cancer cell lines. (A–C) Western blot images of BxPC3, PANC-1, and MIA PaCa-2 cells, respectively, in which cells were starved for 1 h and treated with 2 μg/mL ephrinA1-Fc or the indicated doses of targefrin, targefrin-PTX, targefrin-dimer, and targefrin-dimer-PTX for 3 h. (D–F) Densitometry analyses of (A–C), respectively. EphA2/β-actin ratios were normalized by designating the EphA2 expression from the DMSO control condition as 100% for (A–C) or 1 for (D–F). ***p < 0.001, ****p < 0.0001, as determined by a one-way analysis of variance using Dunnett’s post-test analysis.